Altamira Therapeutics Ltd. (CYTO)의 가격은 얼마입니까?

Altamira Therapeutics Ltd. (CYTO)의 가격은 $0.3입니다.

Altamira Therapeutics Ltd. (CYTO)의 시가 총액은 무엇입니까?

Altamira Therapeutics Ltd. (CYTO)의 시가 총액은 $1.13M입니다.

Altamira Therapeutics Ltd. (CYTO) 액면분할

Altamira Therapeutics Ltd. is a biotechnology firm dedicated to pioneering new treatments for critical medical needs that are currently underserved. Its marketed offerings include Bentrio, a non-pharmaceutical nasal spray designed for individual protection against prevalent airborne viruses and allergens. The company is also heavily invested in developing RNA therapeutics specifically for extrahepatic targets. This includes their preclinical OligoPhore and SemaPhore platforms, engineered for the effective delivery of oligonucleotides and mRNA. In its clinical-stage portfolio, AM-125 is undergoing Phase II trials for the intranasal treatment of vertigo. Additionally, Keyzilen and Sonsuvi are both in Phase III clinical development; Keyzilen is focused on acute inner ear tinnitus, and Sonsuvi addresses acute inner ear hearing loss. Established in 2003 and headquartered in Hamilton, Bermuda, Altamira Therapeutics conducts operations across Switzerland, the United States, Europe, and Australia. The company officially adopted the name Altamira Therapeutics Ltd. in July 2021, prior to which it was known as Auris Medical Holding Ltd.

연도	주식 분할	배수	누적 배수
제공된 날짜에 대한 데이터가 충분하지 않습니다.

연도

주식 분할

배수

누적 배수

제공된 날짜에 대한 데이터가 충분하지 않습니다.

회사	주식 분할 횟수	누적 배수	국가
Vertex Pharmaceuticals Incorporated VRTX.US	1	x2	US
Argenx SE ARGX.US	0	-	NL
Lonza Group AG LONN.SW	0	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	0	-	KR
UCB S.A. UCB.BR	0	-	BE

회사

주식 분할 횟수

누적 배수

국가